BRPI0921392A2 - inibidores quinase com perfil de segurança cyp aperfeiçoado - Google Patents

inibidores quinase com perfil de segurança cyp aperfeiçoado

Info

Publication number
BRPI0921392A2
BRPI0921392A2 BRPI0921392A BRPI0921392A BRPI0921392A2 BR PI0921392 A2 BRPI0921392 A2 BR PI0921392A2 BR PI0921392 A BRPI0921392 A BR PI0921392A BR PI0921392 A BRPI0921392 A BR PI0921392A BR PI0921392 A2 BRPI0921392 A2 BR PI0921392A2
Authority
BR
Brazil
Prior art keywords
cypase
inhibitors
safety profile
improved cyp
cyp
Prior art date
Application number
BRPI0921392A
Other languages
English (en)
Inventor
Michael L Curtin
Michael R Michaelides
Robin R Frey
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0921392A2 publication Critical patent/BRPI0921392A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0921392A 2008-12-05 2009-12-04 inibidores quinase com perfil de segurança cyp aperfeiçoado BRPI0921392A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12028108P 2008-12-05 2008-12-05
US22376009P 2009-07-08 2009-07-08
PCT/US2009/066725 WO2010065825A2 (en) 2008-12-05 2009-12-04 Kinase inhibitors with improved cyp safety profile

Publications (1)

Publication Number Publication Date
BRPI0921392A2 true BRPI0921392A2 (pt) 2016-04-26

Family

ID=41559043

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921392A BRPI0921392A2 (pt) 2008-12-05 2009-12-04 inibidores quinase com perfil de segurança cyp aperfeiçoado

Country Status (25)

Country Link
US (2) US20100144783A1 (pt)
EP (1) EP2373662B1 (pt)
JP (1) JP5588458B2 (pt)
KR (1) KR101639642B1 (pt)
CN (1) CN102239171B (pt)
AR (1) AR074481A1 (pt)
AU (1) AU2009322270B2 (pt)
BR (1) BRPI0921392A2 (pt)
CA (1) CA2743592A1 (pt)
CL (1) CL2011001312A1 (pt)
CO (1) CO6382131A2 (pt)
DO (1) DOP2011000153A (pt)
EC (1) ECSP11011172A (pt)
ES (1) ES2524966T3 (pt)
IL (1) IL212716A (pt)
MX (1) MX2011005943A (pt)
MY (1) MY179042A (pt)
NZ (1) NZ592714A (pt)
PA (1) PA8852401A1 (pt)
PE (1) PE20110830A1 (pt)
RU (2) RU2480472C2 (pt)
TW (2) TWI441827B (pt)
UA (1) UA103351C2 (pt)
UY (1) UY32291A (pt)
WO (1) WO2010065825A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
CN102239171B (zh) * 2008-12-05 2014-06-11 艾伯维巴哈马有限公司 作为激酶抑制剂用于治疗癌症的噻吩并[3,2-c]吡啶衍生物
WO2011156473A1 (en) * 2010-06-09 2011-12-15 Abbott Laboratories Crystalline forms of kinase inhibitors
TWI482770B (zh) * 2010-06-09 2015-05-01 Abbvie Bahamas Ltd 結晶型激酶抑制劑
BR112012031516A2 (pt) * 2010-06-09 2016-11-08 Abbott Lab dispersões sólidas contendo inibidores de quinase
TWI492949B (zh) 2010-06-09 2015-07-21 Abbvie Bahamas Ltd 結晶型激酶抑制劑
US8911725B2 (en) 2010-06-23 2014-12-16 University Of Central Florida Research Foundation, Inc. Co-targeting of aurora A kinase and LIM kinase 1 for cancer therapy
US8436179B2 (en) 2011-07-20 2013-05-07 Abbvie Inc. Kinase inhibitor with improved solubility profile
PE20142103A1 (es) 2011-12-14 2015-01-11 Abbvie Inc Composiciones que contienen inhibidores de quinasas
CN104736533B (zh) * 2012-08-17 2016-12-07 癌症治疗合作研究中心有限公司 Vegfr3抑制剂
HK1209104A1 (en) * 2012-08-17 2016-03-24 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
WO2015157360A1 (en) 2014-04-08 2015-10-15 Abbvie Inc. Processes to make protein kinase inhibitors
US20170197980A1 (en) * 2014-06-25 2017-07-13 Abbvie Inc. N-(4-phenyl)-n'-(3-fluorophenyl)urea docusate
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CA3141405A1 (en) * 2019-06-12 2020-12-17 H. Charles Manning Amino acid transport inhibitors and the uses thereof
KR20230019110A (ko) * 2020-05-11 2023-02-07 유니버시티 헬스 네트워크 4-아미노-5-(6-(4-메틸피페라진-1-일)-1H-벤조[D]이미다졸-2-일)티에노[2,3-b]피리딘-6(7H)-온(one)의 염 및 결정형

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1188529A (en) 1966-06-09 1970-04-15 Wellcome Found Pyramidine Derivatives
US4357535A (en) 1980-04-30 1982-11-02 North American Philips Corporation Apparatus for inspecting hand-held articles and persons carrying same
GB8307154D0 (en) 1983-03-15 1983-04-20 Mk Electric Ltd Terminals
US4767766A (en) 1987-01-30 1988-08-30 Merck & Co., Inc. Derivatives of 3-hydroxyazabenzo(B)thiophene useful as 5-lipoxygenase inhibitors
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0436810Y2 (pt) 1987-12-29 1992-08-31
US4843949A (en) 1988-08-29 1989-07-04 Pneumo Abex Corporation Fluid control valve with variable pressure gain
GB8912498D0 (en) 1989-05-31 1989-07-19 De Beers Ind Diamond Diamond growth
EP0438261A3 (en) 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0630031B1 (en) 1993-06-16 2002-08-14 E.I. Du Pont De Nemours And Company Water cleanable thick film paste composition
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
DE29511756U1 (de) 1995-07-20 1995-09-28 Ferco International Usine de Ferrures de Bâtiment S.A.R.L., Sarrebourg Flügelseitiges Ecklagerbeschlagteil für Drehkippfenster
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
DE19620508A1 (de) 1996-05-22 1997-11-27 Hoechst Ag Schwefelenthaltende heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
US6297261B1 (en) 1997-04-22 2001-10-02 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
BR9812944A (pt) 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
CA2348740A1 (en) * 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
MXPA02002938A (es) 1999-09-17 2004-12-06 Abbott Gmbh & Co Kg Inhibidores de cinasa como agentes agentes terapeuticos.
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
EP2071827A3 (en) 2000-12-15 2010-08-25 BRITISH TELECOMMUNICATIONS public limited company Transmission and reception of audio and/or video material
DE60204674T2 (de) 2001-03-14 2006-05-18 Eli Lilly And Co., Indianapolis Retinoid x rezeptormodulatoren
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
AU2002333524A1 (en) 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
WO2003059354A2 (en) 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
EP1589969A4 (en) 2003-01-17 2008-08-13 Merck & Co Inc 3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
DE10303311A1 (de) * 2003-01-28 2004-07-29 Basf Ag Addukte auf Basis cyclischer Verbindungen und ihre Verwendung als Gerbstoffe und Konservierungsmittel
WO2004100947A2 (en) 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2587464A1 (en) 2004-11-11 2006-05-18 Achillion Pharmaceuticals, Inc. Inhibitors of hiv-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof
AU2006313456B2 (en) 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
US7566721B2 (en) 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
MX2008002207A (es) 2005-08-16 2008-03-27 Memory Pharm Corp Inhibidores de fosfodiesterasa 10.
US20080255184A1 (en) 2005-11-04 2008-10-16 Smithkline Beecham Corporation Thienopyridine B-Raf Kinase Inhibitors
JP5237108B2 (ja) * 2005-12-08 2013-07-17 アボット・ラボラトリーズ タンパク質キナーゼ阻害薬としての９員ヘテロ二環式化合物
AU2007275221A1 (en) 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
CN102239171B (zh) * 2008-12-05 2014-06-11 艾伯维巴哈马有限公司 作为激酶抑制剂用于治疗癌症的噻吩并[3,2-c]吡啶衍生物

Also Published As

Publication number Publication date
MX2011005943A (es) 2011-06-27
WO2010065825A2 (en) 2010-06-10
CL2011001312A1 (es) 2011-10-07
CO6382131A2 (es) 2012-02-15
US20100144783A1 (en) 2010-06-10
WO2010065825A3 (en) 2010-08-26
MY179042A (en) 2020-10-26
IL212716A (en) 2013-10-31
NZ592714A (en) 2013-03-28
AU2009322270B2 (en) 2014-12-18
UY32291A (es) 2010-07-30
KR101639642B1 (ko) 2016-07-14
TWI441827B (zh) 2014-06-21
TW201431862A (zh) 2014-08-16
EP2373662B1 (en) 2014-09-24
RU2012156958A (ru) 2014-06-27
AU2009322270A1 (en) 2011-07-14
EP2373662A2 (en) 2011-10-12
DOP2011000153A (es) 2011-06-30
HK1159628A1 (en) 2012-08-03
TW201026706A (en) 2010-07-16
IL212716A0 (en) 2011-07-31
PA8852401A1 (es) 2010-07-27
CN102239171A (zh) 2011-11-09
JP5588458B2 (ja) 2014-09-10
RU2480472C2 (ru) 2013-04-27
CN102239171B (zh) 2014-06-11
ES2524966T3 (es) 2014-12-16
JP2012511016A (ja) 2012-05-17
PE20110830A1 (es) 2011-12-14
KR20110091577A (ko) 2011-08-11
ECSP11011172A (es) 2011-08-31
AR074481A1 (es) 2011-01-19
CA2743592A1 (en) 2010-06-10
RU2011127451A (ru) 2013-01-10
TWI500621B (zh) 2015-09-21
US20120309783A1 (en) 2012-12-06
UA103351C2 (uk) 2013-10-10
US8722890B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
BRPI0921392A2 (pt) inibidores quinase com perfil de segurança cyp aperfeiçoado
HUS000513I2 (hu) Relebaktám vagy monohidrátja
DK2245130T3 (da) Ts23 -alpha-amylasevarianter med ændrede egenskaber
BRPI0921327A2 (pt) Combinação de herbicida-protetor
EP2486509A4 (en) PLATFORM SECURITY
BRPI0913642A2 (pt) produtos de combinação
BRPI0922728A2 (pt) combinação de herbicida-antídoto
DK2240506T3 (da) IAP inhibitorer
FI20085696A0 (fi) Liesiturvajärjestelmä
DK2163699T3 (da) Forbindelsesprofil
ES1069811Y (es) Apero manual
BRPI0921952A2 (pt) perfil de vedação
IT1391542B1 (it) Cassaforte
DE502009000386D1 (de) Sicherungseinrichtung
DK2326372T3 (da) Sikkerhedssprøjte
ATE537394T1 (de) Sicherheitsventil
ES1068411Y (es) Cerradura de seguridad
ES1068438Y (es) Tarima alistonada
TH0901005475A (th) สารยับยั้งไคเนสซึ่งมีโพรไฟล์ด้านความปลอดภัยของ cyp ที่ดีขึ้น
ITLT20080001A1 (it) Valvola di sicurezza
UA18258S (uk) Профіль
UA17414S (uk) Профіль
UA17416S (uk) Профіль
UA17415S (uk) Профіль
UA18257S (uk) Профіль

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: ABBOTT LABORATORIES (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25B Requested transfer of rights rejected

Owner name: ABBOTT LABORATORIES (US)

B25B Requested transfer of rights rejected

Owner name: ABBOTT LABORATORIES (US)